Trial Profile
A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Fosnetupitant (Primary) ; Cisplatin; Dexamethasone; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 16 Sep 2023 Results of pooled Pooled Analysis from JapicCTI163355, JapicCTI194691 and JapicCTI194611 Studies evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase, published in the Advances in Therapy
- 22 Dec 2022 Status changed from active, no longer recruiting to completed.
- 05 Aug 2019 Results published in the Cancer.